Castaigne S
Département d'hématologie clinique, Hôpital Saint-Louis, Paris, France.
Bull Cancer. 1988;75(9):859-62.
Since 1970, several trials conducted with natural alpha interferon have allowed the recognition of sensitive disorders to this new type of treatment. These studies are ongoing now with recombinant alpha interferons in hairy cell leukaemia, low grade lymphomas, myeloproliferative disorders and myeloma.
自1970年以来，多项使用天然α干扰素进行的试验已使人们认识到某些疾病对这种新型治疗敏感。目前，这些研究正在使用重组α干扰素治疗毛细胞白血病、低度淋巴瘤、骨髓增殖性疾病和骨髓瘤。
